Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study is a phase II clinical trial to evaluate the safety and efficacy of Bortezomib
plus Pegylated liposomal doxorubicin combination therapy in a histologic type of high-grade
serous carcinoma without BRCA mutation among patients with platinum-resistant recurrent
ovarian cancer.